2021 / 04

Next Paper
DOI: 10.47183/mes.2021.045

REVIEW

Cardiovascular comorbidity in patients with nonalcoholic fatty liver disease

Ledovskaya TI1, Statsenko ME2, Turkina SV2, Konyakhina TA1, Yusupov KS1, Gorbacheva EE1,2
About authors

1 Volgograd Medical Clinical Center of FMBA, Volgograd, Russia

2 Volgograd State Medical University, Volgograd, Russia

Correspondence should be addressed: Elena E. Gorbacheva
Kim, d. 24, k. 125, Volgograd, 400001, Russia; ur.xednay@1ilsak

About paper

Author contribution: Ledovskaya TI — conceived the idea, performed data analysis and interpretation; Statsenko ME, Turkina SV — formulated the problem and organized the study; Konyakhina TA — performed literature analysis and research conceptualization; Yusupov KS — searched the literature and wrote the manuscript; Gorbacheva EE — performed data analysis and interpretation.

Received: 2021-12-07 Accepted: 2021-12-20 Published online: 2021-12-22
|
  1. Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovity SV, Drapkina OM, i dr. Nealkogol'naja zhirovaja bolezn' pecheni u vzroslyh: klinika, diagnostika, lechenie. Rekomendacii dlja terapevtov, tret'ja versija. Jeksperimental'naja i klinicheskaja gastrojenterologija. 2021; 185 (1): 4–52. DOI: 10.31146/16828658-ecg-185-1-4-52. Russian.
  2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology ofnonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84.
  3. Calzadilla Bertot L, Adams L. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016; 17: E774. Available from: https://doi.org/10.3390/ijms17050774.
  4. Loomba R, Adams L. The 20% rule of NASH progres-sion: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019; 70: 1885–8. Available from: https: //doi.org/10.1002/ hep.30946.
  5. Drapkina OM, Ivashkin VT. Jepidemiologicheskie osobennosti nealkogol'noj zhirovoj bolezni pecheni v Rossii (rezul'taty otkrytogo mnogocentrovogo prospektivnogo issledovanija nabljudenija DIREG1 01903). Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2014; 24 (4): 32–8. Russian.
  6. Ivashkin VT, Drapkina OM, Maev IV, i dr. Rasprostranennost' nealkogol'noj zhirovoj bolezni pecheni u pacientov ambulatornopoliklinicheskoj praktiki v Rossijskoj Federacii: rezul'taty issledovanija DIREG 2. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2015; 6: 31–41. Russian.
  7. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230: 258–67.
  8. Drapkina OM, Korneeva ON. Metabolicheskij sindrom i serdechno-sosudistye zabolevanija u zhenshhin. Naskol'ko veliko vlijanie pola? Serdce. 2011; 10 (4): 224–8. Russian.
  9. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61: 1547–54. DOI: 10.1002/hep.27368.
  10. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V et al. Fibrosis severity as a determinant of cause-specific mor-tality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018; 155: 443–57. Available from: https://doi.org/10.1053/j.gastr o.2018.04.034.
  11. Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural his-tory of nonalcoholic fatty liver disease: a prospective follow-upstudy with serial biopsies. Hepatol Commun. 2: 2017; 199–210. Available from: https://doi.org/10.1002/hep4.1134.
  12. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not nash predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67: 1265–73. Available from: https://doi.org/10.1016/j.jhep.2017.07.027.
  13. Mantovani A, Ballestri S, Lonardo A, et al. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016; 61: 1246–67. Available from: https://doi. org/10.1007/s10620-016-4040-6.
  14. Drapkina OM, Zyatenkova EV. Ocenka remodelirovanija serdechno-sosudistoj sistemy i tolshhiny jepikardial'nogo zhira u pacientov s hronicheskoj serdechnoj nedostatochnost'ju i metabolicheskim sindromom. Terapevticheskij Arhiv. 2016; 88 (2): 64–70. Russian.
  15. Dedov II, Melnichenko GA, redaktory. Ozhirenie: jetiologija, patogenez, klinicheskie aspekty. M., 2004; 449 s. Russian.
  16. Ivashkin VT, Drapkina OM, Korneeva ON. Klinicheskie varianty metabolicheskogo sindroma. MIA. 2011; 208 s. Russian.
  17. Engeli S, Schling P. The adipose-tissue renin-angiotensinaldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003; 35: 807–25.
  18. Statsenko ME, Turkina SV, Shilina NN, Kosivtsova MA, Bakumov PA. Strukturno-funkcional'nye osobennosti pecheni u bol'nyh s nealkogol'noj zhirovoj bolezn'ju v zavisimosti ot vyrazhennosti ozhirenija. Jeksperimental'naja i klinicheskaja gastrojenterologija. 2018; 9: 38–44. Russian.
  19. Packer M. Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease. Am J Med. 2020; 133: 170–7. Available from: https://doi.org/10.1016/j.amjmed .2019.09.002.
  20. Manzella D, et al. Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab. 2001; 86: 2769–74.
  21. Paolisso G, et al. Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. Am J Cardiol. 1997; 80: 932–37.
  22. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 2005; 90: 6300–2.
  23. Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019; 7: 313–24. Available from: https: //doi.org/10.1016/S2213- 8587(18)30154 -2.
  24. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015; 21 (22): 6820–34. PMID: 26078558.
  25. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012; 32: 945–50.
  26. Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: apopulationbased cohort study. BMJ Open. 2014; 4: e004973.
  27. James S, Abate D, Abate K, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 19902017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018; 392: 1789–858. Available from: https: //doi. org/10.1016/ S0140-6736(18)32279-7.
  28. Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018; 115: 557–68. Available from: https ://doi. org/10.3238/arzte bl.2018.0557.
  29. Aneni E, Oni E, Martin S, et al. Blood pressure is associ- ated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015; 33: 1207–14. Available from: https://doi.org/10.1097/ HJH.0000000000000532.
  30. Vasunta R, Kesäniemi Y, Ylitalo A, Ukkola O. Primary nonalcoholic fatty liver disease in hypertensive patients. J Hypertens. 2012; 30: 2015–9. Available from: https://doi.org/10.1097/ hjh.0b013e32835 76faf.
  31. Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Aust Med J. 2013; 6: 325–30. Available from: https://doi.org/10.4066/AMJ.2013.1648.
  32. Statsenko ME, Streltsova AM, Turovets MI. Vlijanie nealkogol'noj zhirovoj bolezni pecheni na pokazateli arterial'noj zhestkosti i risk serdechno-sosudistyh oslozhnenij u pacientov s arterial'noj gipertenziej. Arhiv vnutrennej mediciny. 2020; 10 (4): 296–304. DOI: 10.20514/2226-6704-2020-10-4-296-304. Russian.
  33. Carnagarin R, Matthews V,. Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. British Journal of Pharmacology. 2019; 176 (12): 1839–52.
  34. Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008; 72: 618–25.
  35. Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonal-coholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015; 274: 693–701.
  36. Emre A, Terzi S, Celiker E, et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for STsegment elevation myocardial infarction. Am J Cardiol. 2015; 116: 1810–4.
  37. Shi KQ, Wu FL, Liu WY, et al. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. Mol Biol Rep. 2014; 41: 4713–20.
  38. Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla V. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017; 11: S209–S216. Available from: https://doi.org/10.1016/j.dsx.2016.12.033.
  39. Keskin M, Hayıroğlu M, Uzun A, et al. Effect of nonalco-holic fatty liver disease on in-hospital and long-term outcomes in patients with st-segment elevation myocardial infarction. Am J Cardiol. 2017; 120: 1720–6. Available from: https://doi.org/10.1016/j. amjcard.2017.07.107.
  40. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11: 639–54.
  41. Targher G, Mantovani A, Pichiri I, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013; 125: 301–9.
  42. Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PloS One. 2013; 8: e57183.
  43. Ozveren O, Izgi C, Eroglu E, et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty liver disease. UltrasonImaging. Epub. 07/08/2015.
  44. Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014; 24: 663–9.
  45. Stacenko M. E., Turkina S. V., Shilina N. N. Porazhenie pecheni u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju ishemicheskogo geneza i saharnym diabetom tipa 2 — kovarnyj tandem: vozmozhnosti dopolnitel'noj organoprotektivnoj terapii. Consilium Medicum. 2016; 18 (5): 103–109. Russian.
  46. Cassidy S, Hallsworth K, Thoma C, et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol. 2015; 14: 23.
  47. VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015; 62: 773–83.
  48. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fattyliver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012; 35: 389–95.
  49. Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Nonalcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest. 2012; 35: 215–8.
  50. Mantovani A, Pernigo M, Bergmini C, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Le. Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE. 2015; 10 (8): 234–9. DOI: 10.1371/journal.pone.0135329.
  51. Statsenko ME, Turkina SV, Kosivtsova MA. Vozmozhnosti korrekcii mikrocirkuljatornyh narushenij pri nealkogol'noj zhirovoj bolezni pecheni u pacientov s hronicheskoj serdechnoj nedostatochnost'ju. Arhiv vnutrennej mediciny. 2016; 6 (6): 42– 47. Russian.